Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
As one of the first Direct Acting Antivirals (DAA), the protease inhibitor Telaprevir (TVR) was available in the European Union from 9/2011 until 9/2016 as a new treatment option for chronic Hepatitis C.Aim. To assess the implementation of therapy stopping rules or shortening of the treatment and th...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2019-01-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/295 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860156887203840 |
|---|---|
| author | T. Berg P. Buggisch D. Hueppe S. Mauss H. Wedemeyer G. Teuber T. Lutz K. Stein S. Wegner H. Hinrichsen |
| author_facet | T. Berg P. Buggisch D. Hueppe S. Mauss H. Wedemeyer G. Teuber T. Lutz K. Stein S. Wegner H. Hinrichsen |
| author_sort | T. Berg |
| collection | DOAJ |
| description | As one of the first Direct Acting Antivirals (DAA), the protease inhibitor Telaprevir (TVR) was available in the European Union from 9/2011 until 9/2016 as a new treatment option for chronic Hepatitis C.Aim. To assess the implementation of therapy stopping rules or shortening of the treatment and their impact on sustained virological response (SVR), as well as the safety and efficacy of the TVR-based therapy during routine daily treatment of patients in Germany.Materials and Methods. 802 patients were assessed (272 treatment naïve, 520 pre-treated) in the noninterventional, multi-center study.Results. 56.6 % of the patients achieved SVR. SVR rate was higher in patients with relapse after previous treatment (68.0 %) than in patients with a previous null-response (31.1 %) and in previously untreated patients (58.1 %). Stopping rule conditions were fulfilled by 3.2 % of patients and it was implemented in 65.4 % of these. 34.3 % of the patients fulfilled the conditions for a therapy shortening. This rule was adhered to in 48.4 % of these, in 34.5 % it was not adhered to. Thus recommendations were not always being followed. Therapy shortening was considered more frequently in previously untreated (54.8 %) than for previously treated patients (24.2 %). Stopping rule application but not shortened treatment reduced therapy costs.Conclusion. The TVR-based therapy represented a breakthrough at that time. Further DAAs have been added as therapeutic options since, increasing the complexity of treatment choice and correct implementation. They represent both an opportunity and a challenge for all those involved.As one of the first Direct Acting Antivirals (DAA), the protease inhibitor Telaprevir (TVR) was available in the European Union from 9/2011 until 9/2016 as a new treatment option for chronic Hepatitis C.Aim. To assess the implementation of therapy stopping rules or shortening of the treatment and their impact on sustained virological response (SVR), as well as the safety and efficacy of the TVR-based therapy during routine daily treatment of patients in Germany.Materials and Methods. 802 patients were assessed (272 treatment naïve, 520 pre-treated) in the noninterventional, multi-center study.Results. 56.6 % of the patients achieved SVR. SVR rate was higher in patients with relapse after previous treatment (68.0 %) than in patients with a previous null-response (31.1 %) and in previously untreated patients (58.1 %). Stopping rule conditions were fulfilled by 3.2 % of patients and it was implemented in 65.4 % of these. 34.3 % of the patients fulfilled the conditions for a therapy shortening. This rule was adhered to in 48.4 % of these, in 34.5 % it was not adhered to. Thus recommendations were not always being followed. Therapy shortening was considered more frequently in previously untreated (54.8 %) than for previously treated patients (24.2 %). Stopping rule application but not shortened treatment reduced therapy costs.Conclusion. The TVR-based therapy represented a breakthrough at that time. Further DAAs have been added as therapeutic options since, increasing the complexity of treatment choice and correct implementation. They represent both an opportunity and a challenge for all those involved. |
| format | Article |
| id | doaj-art-bb40dfa529964b6f85a65bcaf8a5ea10 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2019-01-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-bb40dfa529964b6f85a65bcaf8a5ea102025-02-10T16:14:35ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732019-01-01286152610.22416/1382-4376-2018-28-6-15-26273Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS StudyT. Berg0P. Buggisch1D. Hueppe2S. Mauss3H. Wedemeyer4G. Teuber5T. Lutz6K. Stein7S. Wegner8H. Hinrichsen9University Hospital Leipzig.Ifi-institute for Interdisciplinary Medicine.Center for Hepatogastroenterology.Center for HIV and Hepatogastroenterology.University Hospital Essen, University of Duisburg-Essen.Practice for Gastroenterology and Hepatology.Infektiologikum Frankfurt.University Hospital of Magdeburg.Janssen-Cilag GmbH.Practice for Gastroenterology and Hepatology.As one of the first Direct Acting Antivirals (DAA), the protease inhibitor Telaprevir (TVR) was available in the European Union from 9/2011 until 9/2016 as a new treatment option for chronic Hepatitis C.Aim. To assess the implementation of therapy stopping rules or shortening of the treatment and their impact on sustained virological response (SVR), as well as the safety and efficacy of the TVR-based therapy during routine daily treatment of patients in Germany.Materials and Methods. 802 patients were assessed (272 treatment naïve, 520 pre-treated) in the noninterventional, multi-center study.Results. 56.6 % of the patients achieved SVR. SVR rate was higher in patients with relapse after previous treatment (68.0 %) than in patients with a previous null-response (31.1 %) and in previously untreated patients (58.1 %). Stopping rule conditions were fulfilled by 3.2 % of patients and it was implemented in 65.4 % of these. 34.3 % of the patients fulfilled the conditions for a therapy shortening. This rule was adhered to in 48.4 % of these, in 34.5 % it was not adhered to. Thus recommendations were not always being followed. Therapy shortening was considered more frequently in previously untreated (54.8 %) than for previously treated patients (24.2 %). Stopping rule application but not shortened treatment reduced therapy costs.Conclusion. The TVR-based therapy represented a breakthrough at that time. Further DAAs have been added as therapeutic options since, increasing the complexity of treatment choice and correct implementation. They represent both an opportunity and a challenge for all those involved.As one of the first Direct Acting Antivirals (DAA), the protease inhibitor Telaprevir (TVR) was available in the European Union from 9/2011 until 9/2016 as a new treatment option for chronic Hepatitis C.Aim. To assess the implementation of therapy stopping rules or shortening of the treatment and their impact on sustained virological response (SVR), as well as the safety and efficacy of the TVR-based therapy during routine daily treatment of patients in Germany.Materials and Methods. 802 patients were assessed (272 treatment naïve, 520 pre-treated) in the noninterventional, multi-center study.Results. 56.6 % of the patients achieved SVR. SVR rate was higher in patients with relapse after previous treatment (68.0 %) than in patients with a previous null-response (31.1 %) and in previously untreated patients (58.1 %). Stopping rule conditions were fulfilled by 3.2 % of patients and it was implemented in 65.4 % of these. 34.3 % of the patients fulfilled the conditions for a therapy shortening. This rule was adhered to in 48.4 % of these, in 34.5 % it was not adhered to. Thus recommendations were not always being followed. Therapy shortening was considered more frequently in previously untreated (54.8 %) than for previously treated patients (24.2 %). Stopping rule application but not shortened treatment reduced therapy costs.Conclusion. The TVR-based therapy represented a breakthrough at that time. Further DAAs have been added as therapeutic options since, increasing the complexity of treatment choice and correct implementation. They represent both an opportunity and a challenge for all those involved.https://www.gastro-j.ru/jour/article/view/295hepatitis cdirect acting antivirals (daa)stopping ruleshortening of treatmentsustained virological response (svr) |
| spellingShingle | T. Berg P. Buggisch D. Hueppe S. Mauss H. Wedemeyer G. Teuber T. Lutz K. Stein S. Wegner H. Hinrichsen Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study Российский журнал гастроэнтерологии, гепатологии, колопроктологии hepatitis c direct acting antivirals (daa) stopping rule shortening of treatment sustained virological response (svr) |
| title | Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study |
| title_full | Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study |
| title_fullStr | Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study |
| title_full_unstemmed | Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study |
| title_short | Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study |
| title_sort | real life experiences with telaprevir in the treatment of chronic genotype 1 hepatitis c the teps study |
| topic | hepatitis c direct acting antivirals (daa) stopping rule shortening of treatment sustained virological response (svr) |
| url | https://www.gastro-j.ru/jour/article/view/295 |
| work_keys_str_mv | AT tberg reallifeexperienceswithtelaprevirinthetreatmentofchronicgenotype1hepatitiscthetepsstudy AT pbuggisch reallifeexperienceswithtelaprevirinthetreatmentofchronicgenotype1hepatitiscthetepsstudy AT dhueppe reallifeexperienceswithtelaprevirinthetreatmentofchronicgenotype1hepatitiscthetepsstudy AT smauss reallifeexperienceswithtelaprevirinthetreatmentofchronicgenotype1hepatitiscthetepsstudy AT hwedemeyer reallifeexperienceswithtelaprevirinthetreatmentofchronicgenotype1hepatitiscthetepsstudy AT gteuber reallifeexperienceswithtelaprevirinthetreatmentofchronicgenotype1hepatitiscthetepsstudy AT tlutz reallifeexperienceswithtelaprevirinthetreatmentofchronicgenotype1hepatitiscthetepsstudy AT kstein reallifeexperienceswithtelaprevirinthetreatmentofchronicgenotype1hepatitiscthetepsstudy AT swegner reallifeexperienceswithtelaprevirinthetreatmentofchronicgenotype1hepatitiscthetepsstudy AT hhinrichsen reallifeexperienceswithtelaprevirinthetreatmentofchronicgenotype1hepatitiscthetepsstudy |